Hope-For-HepB Top10 November 2007
Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M.
"A. M. and A. Migliavacca" Center for Liver Disease, Division of Gastroenterology, Department of Medicine, Fondazione Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy.
Gastroenterology. 2007 Nov;133(5):1445-51. Epub 2007 Sep 2.
Rating & Commentary
** Large long-term study confirming that adding adefovir to continued lamivudine therapy in case of lamivudine resistance is effective in clearing HBV DNA in 80% and associated with a low risk of adefovir resistance (4% after 4 years). Cirrhotic patients are still at risk of HCC, but no cirrhotic patient without HCC developed decompensated cirrhosis.
Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, Chao YC, Lee SD, Harris M, Yang J, Colonno R, Brett-Smith H.
Division of Hepatology and Complex GI, California Pacific Medical Center, San Francisco, California, USA.
Gastroenterology. 2007 Nov;133(5):1437-44. Epub 2007 Aug 14
Rating & Commentary
** Follow-up study of patients with HBV DNA fall below 105 copies/ml, but no HBeAg-seroconversion out of the pivotal study in 709 HBeAg-positive patients receiving entecavir or lamivudine for one year. A second year of entecavir treatment showed a progressive incidence of clearance of HBV DNA up to 80% without development of virological breakthrough or genotypic resistance.
Long-term presence of HBV in the sera of chronic hepatitis B patients with HBsAg seroclearance.
Arase Y, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Hosaka T, Sezaki H, Sato J, Kobayashi M, Ikeda K, Kumada H.
Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan. Dit e-mailadres wordt beveiligd tegen spambots. JavaScript dient ingeschakeld te zijn om het te bekijken. . 2007;50(3):161-5. Epub 2007 Jan 26.
Intervirology
Rating & Commentary
* Long-term follow-up study confirming that the majority of hepatitis B patients has still detectable HBV DNA shortly after loss of HBsAg, which decreases to about 14% at 10 years after HBsAg loss.
O'Brien SF, Fearon MA, Yi QL, Fan W, Scalia V, Muntz IR, Vamvakas EC.
National Epidemiology and Surveillance, Canadian Blood Services, 1800 Alta Vista Drive, Ottawa, Ontario, Canada. sheila.o' Dit e-mailadres wordt beveiligd tegen spambots. JavaScript dient ingeschakeld te zijn om het te bekijken. . 2007 Oct;47(10):1809-15.
Transfusion
Rating & Commentary
* Large study in Canadian blood donors showing that occult hepatitis B ( HBsAg-negative, HBV DNA positive) is rare (0.5%) in those repeatedly reactive for anti-HBc. Co-occurrence of HBV DNA positivity with anti-HBs, even with titres over 100 mIU / ml, was found regularly. A lookback did not provide proof of transfusion transmission of HBV from HBV DNA-positive, anti-HBc-reactive, HBsAg-negative donors.
Ahn HJ, Kim MS, Kim YS, Kim SI, Huh KH, Ju MK, Ahn SH, Han KH.
Department of Surgery, Yonsei University Medical Center, Seoul, South Korea.
J Med Virol. 2007 Nov;79(11):1655-63.
Rating & Commentary
* Large detailed study in renal recipients confirming that 10-year patient and graft survival are significantly improved in pre-transplant HBsAg positive patients treated with lamivudine compared with no treatment.
Hui CK, Leung N, Shek TW, Yao H, Lee WK, Lai JY, Lai ST, Wong WM, Lai LS, Poon RT, Lo CM, Fan ST, Lau GK; Hong Kong Liver Fibrosis Study Group.
Department of Medicine,University of Hong Kong, Queen Mary Hospital, Hong Kong
Special Administrative Region (SAR), China.
Dit e-mailadres wordt beveiligd tegen spambots. JavaScript dient ingeschakeld te zijn om het te bekijken.
. 2007 Sep;46(3):690-8.
Hepatology
Rating & Commentary
* Study in 128 HBV infected Chinese patients documenting that also in Chinese patients spontaneous HBeAg seroconversion and HBV DNA <104 copies/ml is often associated with regression of fibrosis
Chu CM, Liaw YF.
Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan.
Gastroenterology. 2007 Nov;133(5):1458-65. Epub 2007 Aug 21.
Rating & Commentary
* Large study showing that after HBeAg seroconversion, reactivation of hepatitis B occurred
at a rate of 3.3% per year. Factors associated with an increased risk of reactivation include
genotype C, male sex, ALT levels >5 x ULN during clearance phase, and age >/=40 years.
Buti M, Mas A, Prieto M, Casafont F, González A, Miras M, Herrero JI, Jardi R, Esteban R.
Hospital General Valle de Hebron and CIBER EHD, Barcelona, Spain. mbuti@vhebronnet. 2007 Sep 15;84(5):650-4.
Transplantation
Rating & Commentary
* Detailed study in 29 liver transplant recipients showing that patients who adhere to long-term prophylaxis with lamivudine after early withdrawal of hepatitis B immune globulin have a low risk of HBV recurrence, similar to those who receive combination prophylaxis.
Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, von Boemmel F, Hoffmann C, Rockstroh J, Stoehr A, Wolf E, Soriano V, Berger F, Berg T, Carlebach A, Schwarze-Zander C, Schürmann D, Jaeger H, Mauss S.
Center for HIV and Hepatogastroenterology, Grafenberger Allee 128a, 40237
Duesseldorf, Germany.
AIDS. 2006 Oct 3;20(15):1951-4.
Rating & Commentary
* Key comparative albeit uncontrolled study comparing combination therapy of tenofovir + lamivudine with tenofovir monotherapy for 2 years. No benefit of combination therapy became apparent.
Incidence of HAV and HBV Infections and Vaccination Rates in Patients With
Autoimmune Liver Diseases.
Wörns MA, Teufel A, Kanzler S, Shrestha A, Victor A, Otto G, Lohse AW, Galle PR, Höhler T.
Department of Internal Medicine I, Johannes Gutenberg-University, Mainz, Germany.
Am J Gastroenterol. 2007 Oct 26; [Epub ahead of print]
Rating & Commentary
* First large retrospective cohort study in 225 patients with autoimmune liver disease showing high rates of susceptibility to hepatitis A and B virus infection. Rates of vaccination against these viruses were low despite official recommendations for vaccination.